NEW YORK, Aug 27 – Incyte and CV Therapeutics said Monday they had agreed to work together to study the role genes play in heart disease, expanding a joint research effort that began in 1998.
Under the terms of the new agreement, the companies, both of Palo Alto, Calif., said they would focus on pinpointing genes associated with atherosclerosis and coronary artery disease.
CV Therapeutics will be responsible for developing biological models for studying the genetic aspect of cardiovascular disease and will supply mRNA from the models to Incyte. In turn, Incyte will generate RNA expression data using its microarray technology.
"Our collaboration with Incyte has been successful in identifying new therapeutic targets such as the ABC1 gene and other undisclosed potential targets, and we look forward to continuing this relationship with our scientific colleagues," Louis Lange, CEO of CV Therapeutics, said in a statement.
"We are committed to studying cardiovascular disease in a genome-wide fashion in order to identify and develop new targets," he added.
Financial terms of the deal were not disclosed.
The companies said that under their previous collaboration they had made a number of discoveries, including determining the ABC1 protein’s role in pumping cholesterol out of cells.